Ter Arkh. 2025 Jun 8;97(5):463-470. doi: 10.26442/00403660.2025.05.203250.
ABSTRACT
AIM: To systematize data on the trends of the prevalence of Helicobacter pylori infection among the Moscow adult population.
MATERIALS AND METHODS: The MEDLINE/PubMed, EMBASE, Google Scholar, and the Russian Science Citation Index were searched for studies published between January 1, 1985, and February 7, 2025, inclusive. Publications were selected based on an analysis of their titles and abstracts. Included were peer-reviewed publications in Russian and English containing data on the prevalence of H. pylori among the adult population of Moscow, studies using validated methods for the diagnosis of H. pylori based on serological, urease respiratory tests, histological and molecular methods, as well as publications containing detailed statistical processing of data suitable for inclusion in the meta-analysis.
RESULTS: The final analysis included seven studies totaling 7,581 subjects (the overall mean age of all subjects was 48.28±13.20 years). The overall prevalence of H. pylori infection in the adult population of Moscow in the analyzed pool of studies for 18 years (2006-2024) was 66.534% (95% confidence interval [CI] 42.097-86.989), including 78.661% (95% CI 59.400-92.910) when using serological diagnostic methods and 48.473% (95% CI 32.331-64.781) when using the 13C-urease respiratory test. Studies conducted before 2015 showed the prevalence of H. pylori infection of 81.294% (95% CI 67.202-92.109), 68.028% (95% CI 29.383-95.895) in 2015-2020, and 39.860% (95% CI 33.993-45.877) after 2020. The meta-regression analysis revealed a statistically significant decrease in the prevalence of H. pylori depending on the year of the study (regression coefficient for the year -4.22 (95% confidence interval -6.27–2.17; p<0,0099).
CONCLUSION: The meta-analysis showed a gradual regression in the prevalence of H. pylori infection in Moscow, the largest metropolis in Russia and Europe. However, infection prevalence in the adult population remains relatively high, supporting the need for continued programs of timely diagnosis of H. pylori and subsequent eradication therapy to reduce the risk of associated diseases.
PMID:40561491 | DOI:10.26442/00403660.2025.05.203250